Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091339861> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2091339861 endingPage "484" @default.
- W2091339861 startingPage "481" @default.
- W2091339861 abstract "The safety of other biologic therapies in rheumatoid arthritis (RA) following B cell-depletion therapy with rituximab has not been established. This retrospective chart review of patients attending an outpatient rheumatology clinic aimed to assess the incidence of adverse events in patients receiving biologic agents to treat RA after an inadequate response or intolerance to rituximab. The charts of 22 patients (18 female; mean age 59 years) were reviewed. Duration of RA was >2 years. Before rituximab, patients had failed one (n = 10), two (n = 4) or three (n = 7) biologic therapies: 1 patient started on rituximab as a first-line biologic. Eighteen patients stopped rituximab due to an inadequate clinical response, while four patients stopped due to adverse events. The mean time to starting a new biologic after rituximab was 4 months, although five patients were started within 1 month of the last rituximab infusion. Abatacept (41%) was the most common biologic used after rituximab. The mean follow-up time from the last rituximab infusion was 14 months. Adverse events occurring after rituximab therapy, but before initiation of a new biologic, included disseminated herpes zoster and aseptic meningitis (both required hospitalization). Adverse events recorded after starting a new biologic post-rituximab included rash, carbuncle, upper respiratory tract infection, urinary tract infection, pneumonia, and eczema, but none was classified as serious. Most of these events occurred in patients receiving abatacept. In conclusion, in this retrospective analysis, no serious adverse events were recorded in patients who received biologic agents following rituximab therapy." @default.
- W2091339861 created "2016-06-24" @default.
- W2091339861 creator A5036424382 @default.
- W2091339861 creator A5037644194 @default.
- W2091339861 creator A5067467795 @default.
- W2091339861 date "2009-12-20" @default.
- W2091339861 modified "2023-09-25" @default.
- W2091339861 title "Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis" @default.
- W2091339861 cites W1967477555 @default.
- W2091339861 cites W1979364075 @default.
- W2091339861 cites W1995001296 @default.
- W2091339861 cites W1995228104 @default.
- W2091339861 cites W1995588846 @default.
- W2091339861 cites W2021081313 @default.
- W2091339861 cites W2144047233 @default.
- W2091339861 cites W2161992900 @default.
- W2091339861 cites W2168711492 @default.
- W2091339861 cites W2170350220 @default.
- W2091339861 cites W2319957449 @default.
- W2091339861 doi "https://doi.org/10.1007/s00296-009-1307-7" @default.
- W2091339861 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3824288" @default.
- W2091339861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20091035" @default.
- W2091339861 hasPublicationYear "2009" @default.
- W2091339861 type Work @default.
- W2091339861 sameAs 2091339861 @default.
- W2091339861 citedByCount "11" @default.
- W2091339861 countsByYear W20913398612012 @default.
- W2091339861 countsByYear W20913398612014 @default.
- W2091339861 countsByYear W20913398612015 @default.
- W2091339861 countsByYear W20913398612016 @default.
- W2091339861 countsByYear W20913398612017 @default.
- W2091339861 countsByYear W20913398612019 @default.
- W2091339861 countsByYear W20913398612021 @default.
- W2091339861 crossrefType "journal-article" @default.
- W2091339861 hasAuthorship W2091339861A5036424382 @default.
- W2091339861 hasAuthorship W2091339861A5037644194 @default.
- W2091339861 hasAuthorship W2091339861A5067467795 @default.
- W2091339861 hasBestOaLocation W20913398611 @default.
- W2091339861 hasConcept C126322002 @default.
- W2091339861 hasConcept C141071460 @default.
- W2091339861 hasConcept C197934379 @default.
- W2091339861 hasConcept C198451711 @default.
- W2091339861 hasConcept C2777575956 @default.
- W2091339861 hasConcept C2778570526 @default.
- W2091339861 hasConcept C2779338263 @default.
- W2091339861 hasConcept C2779605438 @default.
- W2091339861 hasConcept C2780653079 @default.
- W2091339861 hasConcept C71924100 @default.
- W2091339861 hasConceptScore W2091339861C126322002 @default.
- W2091339861 hasConceptScore W2091339861C141071460 @default.
- W2091339861 hasConceptScore W2091339861C197934379 @default.
- W2091339861 hasConceptScore W2091339861C198451711 @default.
- W2091339861 hasConceptScore W2091339861C2777575956 @default.
- W2091339861 hasConceptScore W2091339861C2778570526 @default.
- W2091339861 hasConceptScore W2091339861C2779338263 @default.
- W2091339861 hasConceptScore W2091339861C2779605438 @default.
- W2091339861 hasConceptScore W2091339861C2780653079 @default.
- W2091339861 hasConceptScore W2091339861C71924100 @default.
- W2091339861 hasIssue "4" @default.
- W2091339861 hasLocation W20913398611 @default.
- W2091339861 hasLocation W20913398612 @default.
- W2091339861 hasLocation W20913398613 @default.
- W2091339861 hasLocation W20913398614 @default.
- W2091339861 hasOpenAccess W2091339861 @default.
- W2091339861 hasPrimaryLocation W20913398611 @default.
- W2091339861 hasRelatedWork W2009132808 @default.
- W2091339861 hasRelatedWork W2054241726 @default.
- W2091339861 hasRelatedWork W2056867162 @default.
- W2091339861 hasRelatedWork W2091629131 @default.
- W2091339861 hasRelatedWork W2599087986 @default.
- W2091339861 hasRelatedWork W2801221612 @default.
- W2091339861 hasRelatedWork W2902184252 @default.
- W2091339861 hasRelatedWork W3178040701 @default.
- W2091339861 hasRelatedWork W562161591 @default.
- W2091339861 hasRelatedWork W2185923697 @default.
- W2091339861 hasVolume "31" @default.
- W2091339861 isParatext "false" @default.
- W2091339861 isRetracted "false" @default.
- W2091339861 magId "2091339861" @default.
- W2091339861 workType "article" @default.